Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Thioguanin; Belgium: Lanvis; Czech Republic: Lanvis; Estonia: Lanvis; France: Lanvis; Germany: Thioguanin, Thioguanine; Greece: Lanvis, Thioguanine; Ireland: Lanvis; Italy: Tioguanina; Latvia: Lanvis; Lithuania: Lanvis; Netherlands: Lanvis; Poland: Lanvis; Romania: Lanvis; Slovakia: Lanvis; Spain: Tioguanina; Sweden: Lanvis; UK: Lanvis.

North America

Canada: Lanvis; USA: Thioguanine.

Latin America

Argentina: Lanvis; Brazil: Lanvis.

Drug combinations


Thioguanine: C~5~H~5~N~5~S xH~2~O. Mw: 167.19 (anhydrous). (1) 6H-Purine-6-thione, 2-amino-1,7-dihydro-; (2) 2-Aminopurine-6(1H)-thione. CAS-154-42-7; CAS-5580-03-0 (hemihydrate)(1965).

Pharmacologic Category

Antineoplastic Agents; Antimetabolites; Purine Antagonist. (ATC-Code: L01BB03).

Mechanism of action

Purine analog incorporated into DNA and RNA resulting in blockage of synthesis and metabolism of purine nucleotides.

Therapeutic use

Treatment of acute myelogenous (nonlymphocytic) leukemia. Treatment of chronic myelogenous leukemia and granulocytic leukemia.

Pregnancy and lactiation implications

Potentially teratogenic. Excretion in breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to thioguanine or any component of the formulation. Pregnancy.

Warnings and precautions

Myelosuppression is a common dose-related toxicity (may be delayed). Patients with genetic deficiency of thiopurine methyltransferase (TPMT) or who are receiving drugs which inhibit this enzyme (mesalazine, olsalazine, sulfasalazine) may be highly sensitive to myelosuppressive effects. Not recommended for long-term continuous therapy due to potential for hepatotoxicity (hepatic veno-occlusive disease). Potentially carcinogenic. Use with caution in hepatic and renal impairment. Caution with history of previous therapy resistance with either thioguanine or mercaptopurine (there is usually complete cross-resistance between these two).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart